Furthermore, the success of our approach of dual trans-splicing AAVs to overexpress SCN5A in the heart constitutes the proof-of-concept of future work aimed at developing novel treatment for malignant arrhythmias observed in SCN5A loss-of-function-related channelopathies. The gene discussed is SCN5A; the disease is channelopathy.